COO's $5M Uber Bet Stands Out Amid Activist Exit at Illumina
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Uber Technologies' President and COO Andrew Gordon MacDonald filed two open-market purchases on 8 September, disclosing he spent roughly $5.3 million buying UBER shares at around $75 to $76 apiece on 4 September. His total holding rose to 426,320 shares. A discretionary purchase at that size from an operating executive carries real weight.
At ILMN, activist fund Corvex Management spent the first week of September unloading more than $54 million worth of Illumina stock, according to filings dated 4 September. Corvex holds a board seat, making the disposal harder to dismiss. Director Keith Meister had already sold a further $18 million at the end of August. Combined, the pair disclosed over $72 million of selling across a two-week window, suggesting fading patience with the genomics firm's recovery.
The most striking single move in recent filings involves EVO. Main shareholder Kenneth Bryan Dart disclosed buying approximately $716 million of Evolution AB shares across two tranches in late July, at prices near 690 to 695 SEK. The filing appeared 26 August. Days later, a separate insider, Michaela von Bahr, sold roughly $8.7 million in smaller tranches at 820 to 835 SEK. The contrast between a massive buy from the principal shareholder and near-simultaneous selling from an associate insider makes the picture at the Swedish live-casino operator unusually layered.
Corvex's exit from Illumina is the clearest near-term signal in the dataset: when an activist with a board seat exits at scale, it typically marks the end of a defined engagement.
Stocks in this article
How this article was generated
- Generated
- 28 Oct 2026, 00:12
- Prompt version
- v1.0
- Data sources
- Institutional positioningAlt DataIndex Rebalance
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.